Aardvark Therapeutics, Inc. Common Stock Asset Resilience Ratio
Aardvark Therapeutics, Inc. Common Stock asset resilience ratio. Aardvark Therapeutics, Inc. Common Stock (AARD) has an Asset Resilience Ratio of 65.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aardvark Therapeutics, Inc. Common Stock (AARD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Asset resilience ratio of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. This chart shows how Aardvark Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read AARD current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aardvark Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Aardvark Therapeutics, Inc. Common Stock (AARD) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $87.06 Million | 65.35% |
| Total Liquid Assets | $87.06 Million | 65.35% |
Asset Resilience Insights
- Very High Liquidity: Aardvark Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 65.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aardvark Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Aardvark Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Aardvark Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2022–2024)
Aardvark Therapeutics, Inc. Common Stock asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Aardvark Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.51% | $12.02 Million | $77.51 Million | +13.10pp |
| 2023-12-31 | 2.41% | $254.00K | $10.54 Million | -0.85pp |
| 2022-12-31 | 3.26% | $546.00K | $16.76 Million | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more